Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACP-103 + risperidone
- Development stage
- Discontinued
- Lead developer
- Acadia Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ACP-103 + risperidone is a **combination therapy** composed of ACP-103 (also known as pimavanserin) and risperidone. ACP-103 is a small molecule discovered and developed by Acadia Pharmaceuticals and acts as a potent and selective **inverse agonist of the serotonin 5-HT2A receptor**. Risperidone is a widely used atypical antipsychotic with dopamine D2 receptor and serotonin 5-HT2A receptor antagonist properties. This combination has been investigated primarily for use in **schizophrenia** to enhance antipsychotic efficacy and reduce side effects (such as hyperprolactinemia and motor disturbances) that are associated with D2 antagonism from antipsychotic drugs like risperidone. Preclinical and clinical studies suggest that combining ACP-103 with risperidone may improve efficacy and side effect profiles compared to risperidone alone[1][2][3][4][5][6].
- Other names
- pimavanserin + risperidone
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on ACP-103 + risperidone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACP-103 + risperidone.